ArticleDiscover oncology2026
Construction and validation of a novel prognostic risk model in cervical cancer: integrating lactylation-related genes linked to radiotherapy‑associated transcriptional changes.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe association between lactylation and tumor radiotherapy has become a widely studied hotspot. However, the prognostic value of lactylation-related genes (LRGs) linked to radiotherapy‑associated transcriptional changes in cervical cancer remains unclear.
methodsBased on gene expression data from public databases and LRGs, we identified key genes for cervical cancer prognostics and verified their expression levels. Subsequently, LASSO regression with 10-fold cross-validation was used for model construction and internal validation. Patients were divided into different groups according to the optimal cut-off value of risk score, and their differences in biological function/pathway, immunoregulation, and tumor mutation burden (TMB) were analyzed. A nomogram for predicting the survival probability was also constructed.
resultsOur study identified two key genes (RFC4 and STMN1), whose expression was upregulated in tumor tissues but significantly downregulated during radiotherapy. The risk model incorporating the two genes was verified internally and exhibited favourable prognostic stratification capability. Patients were divided into high- and low-risk groups; differentially expressed genes between the groups were significantly enriched for immune-, angiogenesis-, and metabolism-related functions/pathways. Furthermore, the two groups exhibited distinct immune cell infiltration levels and gene mutation, with the low-risk group showing superior survival outcomes. Multivariate Cox analysis identified risk score, overall stage, and T stage as independent prognostic factors (P < 0.05). The nomogram incorporating these factors effectively predicted 1-year, 2-year, and 3-year survival rates.
conclusionThis study provides a promising prognostic model for risk stratification of cervical cancer patients and identifies two biomarkers, which will help promote the understanding of the relationship between radiotherapy, lactylation, and prognosis in cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.